Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259807 | 0.86 | FFAR1 (0.47) | HTR2CLMNAFFAR1 | |
| SCHEMBL259553 | 0.86 | MAPT (0.39) | HTR2CKDM4EALDH1A1LMNAFFAR1 | |
| SCHEMBL260208 | 0.86 | HTR2B (0.43) | HTR2CKDM4EALDH1A1LMNAFFAR1 | |
| SCHEMBL259269 | 0.85 | TP53 (0.39) | HTR2CLMNAFFAR1 | |
| SCHEMBL264042 | 0.83 | FFAR1 (0.40) | HTR2CLMNAFFAR1 | |
| SCHEMBL260362 | 0.83 | P2RX7 (0.41) | HTR2CKDM4EALDH1A1LMNAFFAR1 | |
| SCHEMBL264117 | 0.83 | TP53 (0.42) | LMNAFFAR1 | |
| SCHEMBL260042 | 0.82 | TP53 (0.49) | ALDH1A1LMNAFFAR1 | |
| SCHEMBL259567 | 0.81 | CYP1A2 (0.33) | ALDH1A1LMNA | |
| SCHEMBL263990 | 0.80 | FFAR1 (0.37) | LMNAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | claimed |
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-7968575-B2 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2011-06-28 | — | — | US | disclosed |
| US-7968575-B2 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2011-06-28 | — | — | US | disclosed |
| US-7579477-B2 | Thiazole-based nitric oxide donors having alkyl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2009-08-25 | — | — | US | disclosed |
| US-7579477-B2 | Thiazole-based nitric oxide donors having alkyl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2009-08-25 | — | — | US | disclosed |
| US-7498445-B2 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2009-03-03 | — | — | US | disclosed |
| US-7498445-B2 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2009-03-03 | — | — | US | disclosed |
| US-20080233163-A1 | Thiazole-based Nitric Oxide donors having Acyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2008-09-25 | — | — | US | disclosed |
| US-7332513-B2 | Thiazole-based nitric oxide donors having acyl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2008-02-19 | — | — | US | disclosed |
| US-7189750-B2 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2007-03-13 | — | — | US | disclosed |
| US-7189750-B2 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2007-03-13 | — | — | US | disclosed |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233163-A1 | Thiazole-based Nitric Oxide donors having Acyl substuent(s) and uses thereof | NOS2, NOS1, SQOR | HTR2C 1518/4885ALOX15 96/4885KDM4E 2857/4885 |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | NOS2, NOS1, NOS3 | HTR2C 1520/4885ALOX15 395/4885KDM4E 3902/4885 |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | NOS2, NOS1, NOS3 | HTR2C 711/4885ALOX15 325/4885KDM4E 2951/4885 |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | NOS2, NOS1, SQOR | HTR2C 1518/4885ALOX15 96/4885KDM4E 2857/4885 |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | NOS2, NOS1, NOS3 | HTR2C 1300/4885ALOX15 292/4885KDM4E 3954/4885 |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | NOS2, NOS1, NOS3 | HTR2C 1620/4885ALOX15 111/4885KDM4E 3084/4885 |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | NOS1, NOS2, NOS3 | HTR2C 959/4885ALOX15 88/4885KDM4E 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.